CIBC Asset Management’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $4.08M | Buy |
7,537
+1,252
| +20% | +$647K | 0.01% | 552 |
|
|
2026
Q2 | $3.41M | Buy |
6,285
+3,820
| +155% | +$2.15M | 0.01% | 578 |
|
|
2026
Q1 | $1.46M | Buy |
2,465
+349
| +16% | +$174K | ﹤0.01% | 670 |
|
|
2025
Q4 | $1.03M | Buy |
2,116
+490
| +30% | +$228K | ﹤0.01% | 703 |
|
|
2025
Q3 | $682K | Sell |
1,626
-45
| -3% | -$15.1K | ﹤0.01% | 726 |
|
|
2025
Q2 | $480K | Sell |
1,671
-3
| -0.2% | -$897 | ﹤0.01% | 770 |
|
|
2025
Q1 | $516K | Buy |
1,674
+76
| +5% | +$26K | ﹤0.01% | 744 |
|
|
2024
Q4 | $564K | Buy |
1,598
+65
| +4% | +$23.9K | ﹤0.01% | 734 |
|
|
2024
Q3 | $549K | Sell |
1,533
-5
| -0.3% | -$1.69K | ﹤0.01% | 732 |
|
|
2024
Q2 | $490K | Buy |
1,538
+234
| +18% | +$61.9K | ﹤0.01% | 743 |
|
|
2024
Q1 | $300K | Hold |
1,304
| – | – | ﹤0.01% | 834 |
|
|
2023
Q4 | $287K | Hold |
1,304
| – | – | ﹤0.01% | 828 |
|
|
2023
Q3 | $295K | Sell |
1,304
-7
| -0.5% | -$1.61K | ﹤0.01% | 799 |
|
|
2023
Q2 | $289K | Buy |
1,311
+7
| +0.5% | +$1.55K | ﹤0.01% | 825 |
|
|
2023
Q1 | $292K | Buy |
1,304
+132
| +11% | +$32.5K | ﹤0.01% | 816 |
|
|
2022
Q4 | $326K | Sell |
1,172
-572
| -33% | -$144K | ﹤0.01% | 789 |
|
|
2022
Q3 | $365K | Hold |
1,744
| – | – | ﹤0.01% | 831 |
|
|
2022
Q2 | $411K | Sell |
1,744
-127
| -7% | -$25.8K | ﹤0.01% | 785 |
|
|
2022
Q1 | $336K | Hold |
1,871
| – | – | ﹤0.01% | 992 |
|
|
2021
Q4 | $404K | Buy |
1,871
+55
| +3% | +$10.8K | ﹤0.01% | 917 |
|
|
2021
Q3 | $335K | Buy |
1,816
+146
| +9% | +$28.8K | ﹤0.01% | 962 |
|
|
2021
Q2 | $300K | Hold |
1,670
| – | – | ﹤0.01% | 994 |
|
|
2021
Q1 | $279K | Buy |
1,670
+23
| +1% | +$3.84K | ﹤0.01% | 1002 |
|
|
2020
Q4 | $250K | Buy |
+1,647
| New | +$216K | ﹤0.01% | 993 |
|
|
2018
Q1 | – | Sell |
-1,490
| Closed | -$220K | – | 1085 |
|
|
2017
Q4 | $220K | Buy |
+1,490
| New | +$189K | ﹤0.01% | 962 |
|
|
2017
Q1 | – | Sell |
-1,441
| Closed | -$207K | – | 984 |
|
|
2016
Q4 | $207K | Buy |
+1,441
| New | +$184K | ﹤0.01% | 895 |
|
|
2016
Q1 | – | Sell |
-1,401
| Closed | -$219K | – | 963 |
|
|
2015
Q4 | $219K | Buy |
+1,401
| New | +$204K | ﹤0.01% | 830 |
|
|
2015
Q3 | – | Sell |
-1,401
| Closed | -$244K | – | 966 |
|
|
2015
Q2 | $244K | Sell |
1,401
-33
| -2% | -$5.94K | ﹤0.01% | 847 |
|
|
2015
Q1 | $247K | Buy |
+1,434
| New | +$219K | ﹤0.01% | 840 |
|
|
2014
Q4 | – | Sell |
-1,631
| Closed | -$210K | – | 975 |
|
|
2014
Q3 | $210K | Buy |
+1,631
| New | +$168K | ﹤0.01% | 899 |
|
Other funds holding UTHR
CIBC Asset Management's UTHR Position: Q3 2026 in Review
CIBC Asset Management increased its United Therapeutics (UTHR) stake by 20% in Q3 2026, buying an estimated $647K and bringing the position to 7,537 shares worth $4.08M. The position accounts for 0.01% of the portfolio, ranked #552.
CIBC Asset Management first reported a position in UTHR in Q3 2014 and has held it in 30 quarters since. 359 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.
- CIBC Asset Management held 7,537 shares of United Therapeutics worth $4.08M as of Q3 2026.
- CIBC Asset Management bought 1,252 United Therapeutics shares in Q3 2026, an estimated $647K.
- United Therapeutics made up 0.01% of CIBC Asset Management's portfolio in Q3 2026, its #552 holding.
- CIBC Asset Management first reported a position in United Therapeutics in Q3 2014 and has held it in 30 quarters since.
- 359 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.
Based on CIBC Asset Management's 13F filing for Q3 2026, filed 5 Nov 2026.